Compass Capital Management Inc. Sells 2,666 Shares of Stryker Corporation $SYK

Compass Capital Management Inc. reduced its stake in shares of Stryker Corporation (NYSE:SYK) by 1.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 167,427 shares of the medical technology company’s stock after selling 2,666 shares during the quarter. Stryker makes up 3.5% of Compass Capital Management Inc.’s portfolio, making the stock its 6th largest position. Compass Capital Management Inc.’s holdings in Stryker were worth $66,239,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of the stock. Mid American Wealth Advisory Group Inc. acquired a new stake in shares of Stryker during the second quarter valued at $26,000. Sachetta LLC raised its stake in Stryker by 58.7% in the 2nd quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 27 shares during the last quarter. Ridgewood Investments LLC lifted its holdings in Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 30 shares in the last quarter. Ransom Advisory Ltd acquired a new stake in shares of Stryker during the 1st quarter worth about $37,000. Finally, Solstein Capital LLC purchased a new stake in shares of Stryker during the second quarter worth about $43,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Stryker stock opened at $355.74 on Monday. The stock’s 50-day moving average is $374.63 and its 200-day moving average is $381.38. The company has a market cap of $136.04 billion, a price-to-earnings ratio of 47.12, a price-to-earnings-growth ratio of 2.66 and a beta of 0.94. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a 12 month low of $329.16 and a 12 month high of $406.19.

Stryker (NYSE:SYK) last issued its earnings results on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.13 by $0.06. The business had revenue of $6.06 billion during the quarter, compared to analysts’ expectations of $6.04 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The company’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Insider Buying and Selling at Stryker

In other news, Director Ronda E. Stryker sold 276,173 shares of the firm’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the transaction, the director owned 2,702,108 shares of the company’s stock, valued at approximately $954,600,714.24. This trade represents a 9.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Viju Menon sold 500 shares of Stryker stock in a transaction on Monday, August 25th. The shares were sold at an average price of $390.61, for a total transaction of $195,305.00. Following the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 520,500 shares of company stock valued at $184,803,065 in the last three months. Company insiders own 5.90% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on SYK shares. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a research report on Monday, November 3rd. Truist Financial restated a “hold” rating and set a $392.00 price objective (down previously from $407.00) on shares of Stryker in a report on Monday, November 3rd. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Saturday, October 18th. BTIG Research increased their target price on Stryker from $408.00 to $410.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Finally, Rothschild & Co Redburn started coverage on Stryker in a report on Thursday, September 18th. They issued a “neutral” rating and a $420.00 price target for the company. Thirteen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $433.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.